fludarabin review new fluorin adenin analog fludarabin efficaci mani tumor type past ten year similar analog avail commerci use cytarabin antileukem agent vidarabin antivir vidarabin fludarabin resist deactiv adenosin deaminas data phase II trial fludarabin effect number leukemia acut lymphocyt leukemia acut nonlymphocyt leukemia chronic lymphocyt leukemia cll dose adequ respons acut leukemia maximum toler dose intoler granulocytopenia thrombocytopenia life-threaten neurotox syndrom cll dose satisfactori respons limit long-term surviv statist avail histor perspect respons agent increas surviv time toxic dose regimen consecut day somnol metabol acidosi confus fatigu nausea increas serum creatinin aminotransferas concentr pulmonari hepat abnorm mild hematolog toxic dose level 